Amino acids in the sequence GEPPPGKPADDAGLV - an identity fact, not a product claim.
Form Labs catalog recordPlain-English research guideBPC-157 / PL 14736
BPC-157 research guide
Everything worth knowing, without the jargon.
BPC-157 is a synthetic 15-amino-acid peptide, based on a partial sequence of a protective protein found in gastric juice. It's studied - almost entirely in cells and rodents - for how tissues like the gut, tendon and blood vessels repair.
Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.
REV 2026-10 · 1 Oct 20266 peer-reviewed studiesResearch-use-only context
What the papers reportThird-party literature - not product claims
When the protective gastric-juice substance behind BPC-157 was first described.
Sikiric et al., J Physiol Paris, 1993Completed, published human trials so far - the evidence is lab and animal only.
Published researchWhen the first randomised controlled human trial began recruiting (results expected ~2027).
ClinicalTrials.gov - NCT07437547Why it matters
Why is BPC-157 studied?
BPC-157 is studied because it is a synthetic 15-amino-acid peptide (Form Labs catalogue record) based on a partial sequence of a protective protein found in gastric juice. This guide's sources hold a large, decades-long body of animal research on BPC-157 and almost no human evidence. Most of the work is in rats and cell cultures, looking at how the gut, tendons and blood vessels repair.
A lot of animal research, very little in people.
BPC-157 is unusual: it has a big, decades-long body of animal research behind it, and almost no human evidence. Most of the work is in rats and cell cultures, looking at how the gut, tendons and blood vessels repair.
That gap matters. Animal results often don't carry over to people, and here that step has barely been tested - the first properly controlled human trial only began in 2026. So this guide describes what the research looked at and found in its models, not what BPC-157 does in a person.
Study observations
What laboratory observations have BPC-157 studies reported?
Chang et al. (Journal of Applied Physiology, 2011) reported increased tendon-cell growth and migration in culture and different healing measurements in rat tendons after BPC-157. Hsieh et al. (Journal of Molecular Medicine, 2017) reported VEGFR2 signalling and blood-vessel observations in cell and animal models. These findings do not establish clinical outcomes in people.
BPC-157 laboratory observations Findings stay tied to the cited study and its model.
Cell and tendon models
Chang et al. (Journal of Applied Physiology, 2011) reported tendon-cell growth and migration in culture and tendon-healing observations in rats.
Blood-vessel models
Hsieh et al. (Journal of Molecular Medicine, 2017) reported blood-vessel and VEGFR2 signalling observations in cell and animal models.
Animal pharmacokinetics
He et al. (Frontiers in Pharmacology, 2022) measured BPC-157 clearance in rats and dogs; the findings concern those animal models.
Pharmacology at a glance
- Research code
- BPC-157 (PL 14736)
- Class
- A synthetic 15-amino-acid peptide (a 'pentadecapeptide'), studied in tissue-repair research.
- Molecule
- A short, stable lab-made chain of 15 amino acids (GEPPPGKPADDAGLV), based on a partial sequence of a protective protein found in gastric juice.
- Reported half-life
- Short - under about 30 minutes in a rat and dog study that measured how quickly the body cleared it (a pharmacokinetics study).
- Originator
- First described by a University of Zagreb research group (Sikiric and colleagues).
- Approval status
- Not an approved medicine anywhere - a preclinical research compound. A first controlled human trial began in 2026.
What it has been studied for
What has BPC-157 been studied for?
BPC-157 has been studied in five areas: gut and stomach lining, tendon and connective tissue, blood-vessel growth, how the body handles it in rats and dogs (He et al., Frontiers in Pharmacology, 2022), and human evidence. The first four areas are rat, dog and cell-culture work. This guide's FAQ lists ClinicalTrials.gov NCT07437547, a hamstring-injury trial that began recruiting in 2026, with no results recorded here.
Study areas from the published literature.
Gut & stomach lining
The original 'body protection' gastric research (Sikiric), plus rat gut-join healing (Vuksic).
Sikiric et al., 1993; Vuksic et al., 2007Tendon & connective tissue
Tendon healing and fibroblast (tissue-cell) migration in rats and cell cultures.
Chang et al., J Appl Physiol, 2011Blood-vessel growth (angiogenesis)
New-vessel growth and VEGFR2 signalling, in cultured cells and a rat model.
Hsieh et al., J Mol Med, 2017How the body handles it (PK/ADME)
How quickly rats and dogs absorbed and cleared it - a pharmacokinetics study, not an efficacy one.
He et al., Front Pharmacol, 2022Human evidence (pending)
A first randomised controlled human trial (hamstring injury) began recruiting in 2026; results aren't out yet.
ClinicalTrials.gov NCT07437547The studies
What did the BPC-157 studies find?
The six BPC-157 studies cited in this guide are preclinical, from a discovery paper (Sikiric et al., Journal de Physiologie (Paris), 1993) to a pharmacokinetics study (He et al., Frontiers in Pharmacology, 2022). In a rat model, BPC-157 was associated with better healing of an intestinal join (Vuksic et al., Surgery Today, 2007). Chang et al. (Journal of Applied Physiology, 2011) reported tendon cells grew and migrated more and rat tendons healed faster.
Open any study for a plain summary, what it measured, the finding, and a link to the paper.
This is where the idea began: the group described a protective substance they found in gastric juice, and the 'the stomach protects the body' hypothesis behind it. BPC-157 is the stable synthetic peptide later modelled on part of that sequence.
- Studied in
- Rodent models and the original gastric-juice work.
- Design
- A foundational research paper setting out the hypothesis and early findings.
- Measured
- Stomach and other tissue measurements in the group's animal models.
It laid out the 'body protection compound' idea and the early animal observations that led to the synthetic BPC-157 peptide (Sikiric P and colleagues - Journal de Physiologie (Paris) - 1993). It's the origin story, not a trial of the product (Sikiric P and colleagues - Journal de Physiologie (Paris) - 1993).
DOI 10.1016/0928-4257(93)90038-UOne of many rat studies looking at whether BPC-157 changed how a surgical join in the intestine healed.
- Studied in
- Rats (in-vivo).
- Design
- An animal surgical-healing model.
- Measured
- How well an ileoileal (small-intestine) join held and healed.
In this rat model, BPC-157 was associated with better healing of the intestinal join (Vuksic T and colleagues - Surgery Today - 2007). It's an animal result - not a human finding or a product claim (Vuksic T and colleagues - Surgery Today - 2007).
DOI 10.1007/s00595-006-3498-9This study looked at tendon repair two ways: cultured tendon cells in a dish, and a cut Achilles tendon in rats.
- Studied in
- Cultured rat tendon fibroblasts (tissue cells) plus rats.
- Design
- A lab cell study alongside an animal tendon-healing model.
- Measured
- Cell growth and movement in the dish, and tendon healing in the rats.
The tendon cells grew and migrated more in the dish, and the rat tendons were reported to heal faster (Chang C-H and colleagues - Journal of Applied Physiology - 2011). Animal and cell results - not a claim about people (Chang C-H and colleagues - Journal of Applied Physiology - 2011).
DOI 10.1152/japplphysiol.00945.2010This study looked at angiogenesis - the growth of new blood vessels - in cultured cells and in a rat model of poor blood flow.
- Studied in
- Cultured human vascular (blood-vessel) cells plus rats.
- Design
- Lab cell experiments plus a rat hind-limb blood-flow model.
- Measured
- New-vessel growth and a signalling pathway called VEGFR2.
It linked BPC-157 to more new-vessel growth and to VEGFR2 signalling in these models (Hsieh M-J and colleagues - Journal of Molecular Medicine - 2017). Cell and animal findings only (Hsieh M-J and colleagues - Journal of Molecular Medicine - 2017).
DOI 10.1007/s00109-016-1488-yA review paper pulling together decades of mostly-rodent research on wound healing and blood-vessel growth.
- Studied in
- A summary of many earlier animal studies.
- Design
- A narrative review, not a new experiment.
- Measured
- What the collected animal studies reported.
It summarises the animal wound-healing and angiogenesis literature in one place (Seiwerth S and colleagues - Frontiers in Pharmacology - 2021). It's a review of research, not evidence about people (Seiwerth S and colleagues - Frontiers in Pharmacology - 2021).
DOI 10.3389/fphar.2021.627533This study measured how quickly rats and dogs absorbed and cleared BPC-157 - a 'pharmacokinetics' study. It's about handling, not healing.
- Studied in
- Rats and dogs.
- Design
- A pharmacokinetics / ADME study (absorption, distribution, metabolism, excretion).
- Measured
- Blood levels over time, half-life, and how the body cleared it.
He et al. (Frontiers in Pharmacology, 2022) reported a short half-life, under about 30 minutes, in rats and dogs. These are animal pharmacokinetic observations.
DOI 10.3389/fphar.2022.1026182Risks recorded in studies
What risks have BPC-157 studies recorded?
The studies cited in this guide are preclinical, so they do not establish the human safety profile of BPC-157. This guide records a handful of tiny, uncontrolled pilot reports but no completed randomised controlled trial. A large share of the BPC-157 literature comes from the original Zagreb group, with fewer independent replications. Form Labs supplies BPC-157 only as research material.
Human safety is largely unknown
Not establishedBecause there are no completed human trials, the human safety profile isn't established. What's known comes from animal studies and a handful of tiny, uncontrolled pilot reports.
Most evidence is from one research group
A caveatA large share of the BPC-157 literature comes from the original Zagreb group, with fewer independent replications. That's worth knowing when weighing how settled the science is.
Banned in sport
RegulatoryBPC-157 is on the World Anti-Doping Agency prohibited list, so it isn't permitted for athletes. That's context, not use guidance.
Not an approved medicine
RegulatoryNo medicines regulator (the TGA in Australia, the FDA, the EMA) has approved BPC-157 for any use. It's supplied here only as a research material.
This section summarizes third-party trial records. It is not a complete safety profile or advice.
Where evidence stops
What has BPC-157 research not established?
This guide's BPC-157 FAQ record (2026) distinguishes small uncontrolled pilot reports from the absence of a completed randomised controlled trial and lists ClinicalTrials.gov NCT07437547 as recruiting. The cited cell and animal studies do not establish long-term human safety. Findings in those models and the limited human records remain separate evidence categories.
- People: there are no completed, published human trials - the first controlled trial only began in 2026.
- Long-term safety: not established, in animals or people.
- Whether animal results carry over to humans: unknown, and not something this page claims.
Development and status
Is BPC-157 approved, and where does the research stand?
BPC-157 is recorded in this guide's timeline as a preclinical research compound. It begins in 1993 with a protective gastric-juice substance (Sikiric et al., Journal de Physiologie (Paris), 1993), followed by a rat intestinal-join study (Vuksic et al., Surgery Today, 2007) and tendon cell and rat studies (Chang et al., Journal of Applied Physiology, 2011). This guide's timeline lists, for 2026, a first randomised controlled human trial of BPC-157 as beginning recruitment.
A protective substance in gastric juice is described - the origin of the 'body protection compound' idea.
Rat and cell studies look at gut, tendon and connective-tissue healing.
Cell and rat studies look at new-blood-vessel growth (angiogenesis).
A pharmacokinetics study in rats and dogs measures how the body clears it.
The first randomised, controlled human trial begins recruiting. Results are expected around 2027.
Approval status: Not an approved medicine anywhere - a preclinical research compound. A first controlled human trial began in 2026.Whatever the molecule’s status elsewhere, what Form Labs supplies is research-use-only reference material - for laboratory work, not for people or animals.
Evidence and limitations
What does the BPC-157 research mean, and what does it not?
The BPC-157 evidence cited in this guide is preclinical: almost all of it is in cell cultures and rodents, and animal results often do not carry over to people. This guide's limitations and FAQ record only a few small, uncontrolled pilot reports in people, with a first controlled trial listed as beginning recruitment in 2026 (ClinicalTrials.gov NCT07437547). A large part of the BPC-157 literature comes from the original research group, with fewer independent replications than a well-settled field would have.
It's preclinical
Almost all the evidence is in cell cultures and rodents. Animal results often don't carry over to people, and here that step largely hasn't been tested yet.
The human data is tiny
This guide's FAQ record (2026) distinguishes small uncontrolled pilot reports from the absence of a completed randomised controlled trial; it lists a first controlled trial as recruiting. These records do not establish long-term human safety.
Much of it is one group's work
A large part of the literature comes from the original research group, with fewer independent replications than a well-settled field would have.
Where Form Labs fits
This guide is a plain-English summary of published research that Form Labs did not run. It's not medical advice, not a product claim, and not use guidance. We supply BPC-157 strictly as reference material, with a catalog lot record. Matching current certification is unverified.
Lab handling
How is BPC-157 handled as reference material?
BPC-157 is laboratory reference material, not for human consumption or veterinary use. Storage and lot checks follow the product label and any verified matching certificate of analysis (COA). This guide's catalogue record notes storage at 2-8 C and protection from light. Historical sample reports do not verify current lot identity, purity or release status.
Research-use boundary
BPC-157 is supplied strictly for laboratory research. It is not for human consumption, veterinary, medical, or cosmetic use.
Storage
Supplied freeze-dried. Keep it at 2-8 C (fridge-cold) and out of light, following the vial label, any verified matching lab report for the batch, and your lab's own written procedures.
Perth dispatch
Available to Perth researchers as RUO reference material, dispatched from Perth via Australia Post or CouriersPlease. Matching current certification is unverified. For laboratory research use only.
Glossary
Plain-English definitions.
- Peptide
- A short chain of amino acids - the building blocks of proteins.
- Pentadecapeptide
- A peptide made of 15 amino acids, which is what BPC-157 is.
- Preclinical
- Research done in cells and animals, before (or instead of) trials in people.
- In-vitro
- In a dish or test tube, outside a living body.
- In-vivo
- In a living animal.
- Angiogenesis
- The growth of new blood vessels.
- Fibroblast
- A common tissue cell studied in repair research.
- Pharmacokinetics
- How the body absorbs, moves around, and clears a compound - including half-life.
- Half-life
- The time for the amount in the blood to fall by half.
- VEGFR2
- A cell-signalling receptor linked to new-blood-vessel growth.
- Research use only
- Supplied for laboratory research - not for human or animal use, and not a medicine.
FAQ
What are the most common questions about BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide, GEPPPGKPADDAGLV (Form Labs catalogue record), based on a partial sequence of a protective protein found in gastric juice. The most common questions about BPC-157 cover how strong the evidence is, whether BPC-157 has been tested in people, what it is studied for, its half-life, what body protection compound means, how it differs from TB-500, and its Australian status.
BPC-157 is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV), based on a partial sequence of a protective protein found in gastric juice, studied - mostly in cells and rodents - for how tissues repair. BPC-157 isn't an approved medicine.
BPC-157's evidence is almost entirely preclinical - cell cultures and rodents - built up over three decades, but with two big caveats: a large share comes from one originating research group (the University of Zagreb), and there are no completed, published human trials. So the animal findings are extensive, but how they translate to people is genuinely unknown.
Barely. There are no completed, published randomised controlled trials of BPC-157 - only a few very small, uncontrolled pilot reports. The first properly controlled human trial (ClinicalTrials.gov NCT07437547, a hamstring-injury study) began recruiting in 2026, with results expected around 2027.
Published BPC-157 research covers gut and stomach-lining protection (rat ulcer and anastomosis models), tendon and connective-tissue healing (Chang et al., 2011, in rats and cultured cells), blood-vessel growth or angiogenesis (Hsieh et al., 2017), and how the body clears it (He et al., 2022, a rat and dog pharmacokinetics study). All of it is preclinical.
In the one published pharmacokinetics study (He and colleagues, Frontiers in Pharmacology, 2022), BPC-157 had a short half-life - under about 30 minutes - in rats and dogs, and was cleared by the kidneys and bile. That study measured how the body handles the peptide, not what it does, and there is no equivalent human data.
No. 'Body Protection Compound' is a research name from the 1990s, when the original group described a protective substance in gastric juice. In this guide it's a historical label, not a claim. What BPC-157 does in people isn't established.
BPC-157 and TB-500 are unrelated peptides that both appear in tissue-repair research. BPC-157 is a 15-amino-acid peptide based on a gastric-juice protein; TB-500 is a 7-amino-acid fragment of the protein thymosin beta-4. Different origins and sequences, both preclinical. One 2026 rat study (Biçer et al., Joint Diseases and Related Surgery) included both, and this guide draws no combined claim from it.
BPC-157 is a Schedule 4 substance in Australia. The October 2026 Poisons Standard (checked 1 October 2026) lists BPC-157 in Schedule 4 and in Appendix D, clause 5 - the appendix for poisons whose possession without authority is illegal. The TGA's April 2026 examples of unapproved peptide products name BPC-157. Sport Integrity Australia lists BPC-157 as prohibited in sport. Form Labs supplies BPC-157 strictly as laboratory research material, not for human or veterinary use.
Form Labs supplies peptides strictly as laboratory research materials. This guide is a plain-English summary of published research Form Labs did not run - not medical advice, not a product claim, and not guidance for any human or veterinary use.
References
Every figure, sourced.
Educational references to third-party literature. Form Labs is unaffiliated with the study authors.
Foundational paper describing a protective substance in gastric juice and the 'body protection' hypothesis. Sikiric P, et al. Journal de Physiologie (Paris), 1993; 87(5): 313-327.
DOIRat study of intestinal (ileoileal) anastomosis healing. Vuksic T, et al. Surgery Today, 2007; 37: 768-777.
DOIRat and cultured-cell study of tendon healing and fibroblast migration. Chang C-H, et al. Journal of Applied Physiology, 2011; 110(3): 774-780.
DOICell and rat study of angiogenesis and VEGFR2 signalling. Hsieh M-J, et al. Journal of Molecular Medicine, 2017; 95(3): 323-333.
DOIReview of rodent wound-healing and angiogenesis research. Seiwerth S, et al. Frontiers in Pharmacology, 2021; 12: 627533.
DOIPharmacokinetics / ADME study in rats and dogs (how the body clears it). He L, et al. Frontiers in Pharmacology, 2022; 13: 1026182.
DOIRat Achilles tendon study that included BPC-157 and TB-500 together. Biçer O, et al. Joint Diseases and Related Surgery, 2026; 37(3): 822-837.
DOICitations are provided for education only. No therapeutic, weight-loss, or efficacy claims are made.
How we produce these guides
These guides are written and maintained in-house by the Form Laboratories research team. They summarise published literature and link to the cited papers. Form Laboratories did not run those studies. They are not authored by a named clinician and are not medical advice.
Findings remain tied to the study population, model and limits. Cell and animal observations remain separate from clinical results. Everything we supply is research-use-only reference material, not for people or animals.
The product
Form Laboratories - BPC-157
Ready to see BPC-157?
- Check available reports and the tests they cover.
- Compare the listed compound, amount and lot with the report.
- Ships from Perth via Australia Post or CouriersPlease in plain packaging.
Related catalogue records
Compare nearby catalogue records.
These nearby records stay inside the research-only catalogue.
Research-use-only catalogue
Continue to the product record.
Review lot-facing product details, pricing, and checkout boundaries on the matching product page.
View BPC-157 - from $99.00 AUD